INNT News and Press, Innovate Biopharmaceuticals Inc. From 04/26/19

RALEIGH, N.C., April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc.  (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that company executives intend to ho...

Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...

Selected for oral poster tour by the scientific committee in the gut microbiota section at the International Liver Congress TM 2019 of EASL Data presented as a poster showing significant effect on gut epithelial integrity thought to be key for bacterial translocation leading to NAFLD...

Innovate plans to provide an operational progress update, including regarding its first phase 3 celiac disease clinical trial Topline NASH preclinical data expected to be released at the Digestive Disease Week (DDW) medical conference to be held May 18-21, 2019 in San Diego RALEIGH...

RALEIGH, N.C., March 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases with its lead drug comprising a new class of medicines based on gut-res...

Innovate Biopharmaceuticals, Inc. (INNT) Q4 2018 Earnings Conference Call March 19, 2019 08:00 AM ET Company Participants Jennifer Zimmons - Investor Relations Sandeep Laumas - Executive Chairman and Chief Executive Officer Patrick Griffin - Chief Medical Officer Jay Madan - Fo...

Innovate closes an equity financing with gross proceeds of $9.7 million Continued launch activities for start of the first Phase 3 celiac disease trial, expected to start Q2 2019 Continued research collaborations studying new indications for larazotide: known mechanism of action i...

Innovate Biopharmaceuticals (NASDAQ: INNT ): FY GAAP EPS of -$0.98. More news on: Innovate Biopharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that it filed its 2018 Annual Report on F...

Gainers:  Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess...